The Tryton Side Branch Stent was the first dedicated
bifurcation device to receive FDA regulatory approval
in the U.S. in March 2017 for coronary artery disease
(CAD). The technology was granted commercial status to
treat a coronary bifurcation lesion involving a large side
branch (appropriate for a ≥2.5mm stent) following years
of clinical trials and research.
In addition to using the new innovative Tryton Side
Branch Stent, the Fort Worth cardiac catheterization lab
procedure was conducted using the Corindus® robotic
heart catheterization system, one of only three Corindus
robotic systems in the entire Fort Worth/Dallas region.*
“This case was an example of how the expertise of the
interventional cardiologists on the Baylor Scott &
White - Fort Worth medical staff and technology came
together for a safer and improved experience for our heart
patients,” according to Farhan Ali, MD, MA, MPH,
FAC, FSCAI, RPVI, Medical Director for Interventional
Cardiology at Fort Worth. “Because about 25 percent
of patients have plaque build-up along a coronary
artery segment involving a bifurcation anatomy, clinical
treatment of these complex lesions can be challenging,”
Dr. Ali stated. “One approach has been to avoid stenting
the side branch, potentially leaving the vessel subject
to higher rates of restenosis, or future narrowing of the
vessel. Tryton is the first commercially available stent
designed to treat side branch lesions. We are proud that
the team at Baylor Fort Worth is able to bring these
innovations to the region.”
Approximately 20 to 30 percent of all patients undergoing
percutaneous coronary interventions (PCI) to open
blocked arteries have a bifurcation lesion, a condition
resulting from a buildup of plaque at a site where one
artery branches from another. Provisional stenting of the
main branch is the existing approach to care, but in many
cases when the side branch is not stented the artery may
become vulnerable to complications such as occlusion
(narrowing), leading to bailout stenting.
CorPath Robotic Angioplasty image courtesy of Corindus
CORINDUS ® ROBOTIC SYSTEM
Another Fort Worth first in fiscal year 2017 was the robot-assisted technology to perform coronary angioplasties and place
stents as cardiologists on the medical staffs at Baylor Hamilton Heart and Vascular Hospital, together with Baylor Heart
and Vascular Services at Fort Worth, became part of a small group in the state of Texas to begin using the Corindus®
Vascular Robotics CorPath System. The first and only FDA-cleared medical device to bring robotic precision to coronary
angioplasty procedures, the Corindus Robotic System was purchased and placed into use in cardiac cath labs at three
Baylor Scott & White Health facilities – the only locations in North Texas* – offering enhanced visualization of X-ray
images combining robotic-assisted precision to benefit heart patients.
*At the time of printing, Corindus® Vascular Robotics CorPath System was available at Baylor Jack and Jane Hamilton Heart and Vascular Hospital’s location in Fort Worth and Dallas as
well as The Heart Hospital Baylor-Plano.
Even though angioplasty is one of the most frequently performed procedures in the country with more than 900,000 cases
completed annually, the procedure itself has remained largely unchanged for decades until now. This new system provides
interventional cardiologists and catheterization labs innovative technology, positioning Baylor Hamilton Heart and Vascular
Services at Fort Worth as a premier training site for interventional cardiologists and clinical staff from across the U.S.
77